Giuseppe
Emeritus
Source: European Centre for Disease Control and Prevention (ECDC), full PDF document: http://www.ecdc.europa.eu/en/public...luenza-season-risk-assessment-europe-2013.pdf
Abridged version: http://www.flutrackers.com/forum/showpost.php?p=483901&postcount=2
(...)
In the UK (England), a surveillance system with comparable data for both hospital admissions and ICU admissions was established in 2011/12, but reporting through similar systems in 2010/11 showed larger pressures.
Chronic respiratory conditions are to date the most frequently reported underlying clinical risk factor in 2012/13 for ICU admissions reported through the sentinel network.
There has been an apparent rise in Panton?Valentine leukocidin (PVL) pneumonia cases and possible association with influenza.
PVL cytotoxin-producing strains of Staphylococcus aureus (PVL-SA) typically cause skin and soft tissue infections.
They can sometimes cause more severe invasive infections and the association with severe community-acquired pneumonia (CAP) is recognised with high (50?75%) mortality rates reported.
Over the four?week period 6 December 2012 to 7 January 2013, the national UK reference laboratory confirmed 18 cases of severe CAP caused by PVL-SA; all have been admitted to intensive care units and four (22%) have died.
This compares to a national figure of 30?40 PVL-CAP cases per year across England, usually peaking in the winter months.
Fourteen have been due to meticillin-sensitive S. aureus infection and four due to meticillin-resistant S. aureus, associated with a variety of strains.
Most cases have reported an influenza-like prodrome with at least six confirmed with an influenza B co-infection.
Influenza has been circulating in the community in England, with the dominant strain being influenza B.
Cases have been distributed around the country with at least two small household clusters identified.
Patients were aged from four to 63 years (median 41 years) and 11 (61%) were female. Further epidemiological and microbiological work is underway*.
(...)
________________
* For further information, see http://www.hpa.org.uk/hpr/news/#pvlsa and for clinical guidance see http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1267551719486 and http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1218699411960
-
------
Abridged version: http://www.flutrackers.com/forum/showpost.php?p=483901&postcount=2
(...)
In the UK (England), a surveillance system with comparable data for both hospital admissions and ICU admissions was established in 2011/12, but reporting through similar systems in 2010/11 showed larger pressures.
Chronic respiratory conditions are to date the most frequently reported underlying clinical risk factor in 2012/13 for ICU admissions reported through the sentinel network.
There has been an apparent rise in Panton?Valentine leukocidin (PVL) pneumonia cases and possible association with influenza.
PVL cytotoxin-producing strains of Staphylococcus aureus (PVL-SA) typically cause skin and soft tissue infections.
They can sometimes cause more severe invasive infections and the association with severe community-acquired pneumonia (CAP) is recognised with high (50?75%) mortality rates reported.
Over the four?week period 6 December 2012 to 7 January 2013, the national UK reference laboratory confirmed 18 cases of severe CAP caused by PVL-SA; all have been admitted to intensive care units and four (22%) have died.
This compares to a national figure of 30?40 PVL-CAP cases per year across England, usually peaking in the winter months.
Fourteen have been due to meticillin-sensitive S. aureus infection and four due to meticillin-resistant S. aureus, associated with a variety of strains.
Most cases have reported an influenza-like prodrome with at least six confirmed with an influenza B co-infection.
Influenza has been circulating in the community in England, with the dominant strain being influenza B.
Cases have been distributed around the country with at least two small household clusters identified.
Patients were aged from four to 63 years (median 41 years) and 11 (61%) were female. Further epidemiological and microbiological work is underway*.
(...)
________________
* For further information, see http://www.hpa.org.uk/hpr/news/#pvlsa and for clinical guidance see http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1267551719486 and http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1218699411960
-
------